In recent years, many cancer studies have described the crosstalk between the CXCR4/SDF-1 axis and the Akt/mTOR pathway and demonstrated the inhibitory effect of CXCR4 antagonist (AMD3100) on mTOR expression (35). Here, CXCR4 is linked to cancer.